Real‐world use of lecanemab: patient pathway findings from a US multicenter study

Abstract Introduction To ensure Alzheimer’s disease‐modifying treatments can be initiated in diverse populations, efficient pathways to obtain timely diagnoses are required. Methods This interim sub‐analysis of a multicenter US study included cross‐sectional surveys and interviews with neurologists at 12 diverse sites to assess real‐world lecanemab use. Results At survey completion, ∼1342 patients had received lecanemab. Most referrals originated from primary care. Amyloid pathology was confirmed primarily by positron emission tomography (58%) or cerebrospinal fluid (35%), with blood‐based biomarkers (BBMs) increasingly used to reduce diagnostic delays. All sites performed apolipoprotein E4 (APOE ε4) testing to inform risk/benefit decisions. Infusions usually started within 6 months of diagnosis. Delayed/incomplete referrals were identified as the most significant barrier in the current patient pathway. Discussion These findings demonstrate the feasibility of lecanemab integration in diverse clinical settings and highlight the importance of primary care physician engagement, optimization of referral pathways, and expanding BBM use in improving timely diagnosis, equitable access, and early treatment initiation.